Somewhat Positive Media Coverage Somewhat Unlikely to Affect Regenxbio (RGNX) Share Price

News stories about Regenxbio (NASDAQ:RGNX) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Regenxbio earned a news impact score of 0.09 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.691187801342 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

NASDAQ:RGNX traded up $0.50 during trading on Thursday, hitting $29.85. The company had a trading volume of 157,121 shares, compared to its average volume of 390,822. The stock has a market capitalization of $909.44, a PE ratio of -12.08 and a beta of -1.21. Regenxbio has a 1-year low of $16.30 and a 1-year high of $42.00.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.20. The firm had revenue of $2.04 million for the quarter. Regenxbio had a negative net margin of 704.02% and a negative return on equity of 36.48%. sell-side analysts predict that Regenxbio will post -2.44 earnings per share for the current year.

RGNX has been the subject of several research reports. BidaskClub upgraded shares of Regenxbio from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Chardan Capital restated a “buy” rating on shares of Regenxbio in a research note on Monday, December 11th. Raymond James Financial restated a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. Mizuho began coverage on shares of Regenxbio in a research note on Monday, February 12th. They issued a “neutral” rating and a $28.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Thursday, March 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $40.63.

In related news, CFO Vittal Vasista sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $30.16, for a total value of $150,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $27.33, for a total transaction of $273,300.00. Following the completion of the sale, the insider now directly owns 248,530 shares in the company, valued at $6,792,324.90. The disclosure for this sale can be found here. Insiders sold 65,000 shares of company stock worth $1,960,200 over the last ninety days. 17.00% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Regenxbio (RGNX) Share Price” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/29/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-regenxbio-rgnx-share-price/1972484.html.

About Regenxbio

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.